5 days ago
Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)
Kepler Capital analyst Jon Berggren maintained a Buy rating on Swedish Orphan Biovitrum AB (0MTD – Research Report) on June 4 and set a price target of SEK350.00. The company's shares closed last Wednesday at SEK303.25.
Confident Investing Starts Here:
Berggren covers the Healthcare sector, focusing on stocks such as Swedish Orphan Biovitrum AB, Herantis Pharma, and Nightingale Health Oyj Class B. According to TipRanks, Berggren has an average return of 9.5% and a 55.10% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Swedish Orphan Biovitrum AB with a SEK363.00 average price target.
Based on Swedish Orphan Biovitrum AB's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of SEK6.47 billion and a net profit of SEK875 million. In comparison, last year the company earned a revenue of SEK6.26 billion and had a net profit of SEK800 million
